Patient characteristics at baseline according to treatment group
| Characteristic . | Overall population . | R(G)-ACVBP . | R(G)-CHOP14 . | R-CHOP21 . |
|---|---|---|---|---|
| No. of patients | 313 | 180 (57.5%) | 76 (24.3%) | 57 (18.2%) |
| Age, median [min-max], y | 32 [18-88] | 29.5 [18-62] | 33 [18-62] | 40 [19-88] |
| Age >60 y | 14 (4.5%) | 2 (1.1%) | 2 (2.6%) | 10 (17.5%) |
| Female | 190 (60.7%) | 113 (62.8%) | 40 (52.6%) | 37 (64.9%) |
| ECOG 0-1 | 252 (81.8%) | 145 (81%) | 59 (81.9%) | 48 (84.2%) |
| Ann Arbor stage I-II | 180 (57.5%) | 100 (55.6%) | 41 (53.9%) | 39 (68.4%) |
| Elevated LDH | 256 (81.8%) | 151 (83.9%) | 67 (88.2%) | 38 (66.7%) |
| IPI 0 | 33 (10.5%) | 17 (9.7%) | 5 (6.9%) | 11 (19.6%) |
| IPI 1-2 | 190 (60.7%) | 108 (61.4%) | 45 (62.5%) | 37 (66.1%) |
| IPI 3-5 | 79 (26.2%) | 51 (29%) | 21 (29.6%) | 7 (12.7%) |
| CNS IPI 0-1 | 157 (52%) | 86 (48.9%) | 38 (53.5%) | 33 (60%) |
| CNS IPI 2-3 | 110 (36.4%) | 69 (39.2%) | 23 (32.4%) | 18 (32.7%) |
| CNS IPI 4-6 | 35 (11.6%) | 21 (11.9%) | 10 (14.1%) | 4 (7.3%) |
| Bulky mass ≥10 cm | 182 (58.5%) | 103 (57.9%) | 45 (59.2%) | 34 (59.6%) |
| Baseline TMTV, median [min-max], cm3 | 261 [2.46-1595.2] | 267.8 [14.1-1403.6] | 333.6 [20.2-1595.2] | 219.4 [2.46-1359.6] |
| Maximal mass diameter, median [min-max], mm | 100 [5.5-240] | 99 [5.5-180] | 103.5 [5.8-180] | 106.5 [9-240] |
| Pericardial and/or pleural effusion | 156 (49.8%) | 90 (50%) | 42 (55.3%) | 24 (42.1%) |
| G-CSF use | 299 (95.5%) | 179 (99.4%) | 74 (97.4%) | 46 (80.7%) |
| Included in a clinical trial | 48 (15.3%) | 24 (13.4%) | 19 (25%) | 5 (8.8%) |
| Extranodal invasion | 151 (48.2%) | 96 (53.6%) | 31 (40.8%) | 24 (42.1%) |
| Follow-up, median [min-max], mon | 44.6 [1-152.7] | 46.5 [1-152.7] | 47.7 [2.9-124.4] | 33.3 [1.8 -135.6] |
| Characteristic . | Overall population . | R(G)-ACVBP . | R(G)-CHOP14 . | R-CHOP21 . |
|---|---|---|---|---|
| No. of patients | 313 | 180 (57.5%) | 76 (24.3%) | 57 (18.2%) |
| Age, median [min-max], y | 32 [18-88] | 29.5 [18-62] | 33 [18-62] | 40 [19-88] |
| Age >60 y | 14 (4.5%) | 2 (1.1%) | 2 (2.6%) | 10 (17.5%) |
| Female | 190 (60.7%) | 113 (62.8%) | 40 (52.6%) | 37 (64.9%) |
| ECOG 0-1 | 252 (81.8%) | 145 (81%) | 59 (81.9%) | 48 (84.2%) |
| Ann Arbor stage I-II | 180 (57.5%) | 100 (55.6%) | 41 (53.9%) | 39 (68.4%) |
| Elevated LDH | 256 (81.8%) | 151 (83.9%) | 67 (88.2%) | 38 (66.7%) |
| IPI 0 | 33 (10.5%) | 17 (9.7%) | 5 (6.9%) | 11 (19.6%) |
| IPI 1-2 | 190 (60.7%) | 108 (61.4%) | 45 (62.5%) | 37 (66.1%) |
| IPI 3-5 | 79 (26.2%) | 51 (29%) | 21 (29.6%) | 7 (12.7%) |
| CNS IPI 0-1 | 157 (52%) | 86 (48.9%) | 38 (53.5%) | 33 (60%) |
| CNS IPI 2-3 | 110 (36.4%) | 69 (39.2%) | 23 (32.4%) | 18 (32.7%) |
| CNS IPI 4-6 | 35 (11.6%) | 21 (11.9%) | 10 (14.1%) | 4 (7.3%) |
| Bulky mass ≥10 cm | 182 (58.5%) | 103 (57.9%) | 45 (59.2%) | 34 (59.6%) |
| Baseline TMTV, median [min-max], cm3 | 261 [2.46-1595.2] | 267.8 [14.1-1403.6] | 333.6 [20.2-1595.2] | 219.4 [2.46-1359.6] |
| Maximal mass diameter, median [min-max], mm | 100 [5.5-240] | 99 [5.5-180] | 103.5 [5.8-180] | 106.5 [9-240] |
| Pericardial and/or pleural effusion | 156 (49.8%) | 90 (50%) | 42 (55.3%) | 24 (42.1%) |
| G-CSF use | 299 (95.5%) | 179 (99.4%) | 74 (97.4%) | 46 (80.7%) |
| Included in a clinical trial | 48 (15.3%) | 24 (13.4%) | 19 (25%) | 5 (8.8%) |
| Extranodal invasion | 151 (48.2%) | 96 (53.6%) | 31 (40.8%) | 24 (42.1%) |
| Follow-up, median [min-max], mon | 44.6 [1-152.7] | 46.5 [1-152.7] | 47.7 [2.9-124.4] | 33.3 [1.8 -135.6] |
ECOG, Eastern Cooperative Oncology Group performance status; G, obinutuzumab; G-CSF, granulocyte colony-stimulating factor; LDH, lactate dehydrogenase; min-max, minimum–maximum.